📰 JOHNSON & JOHNSON FULL STOCK ANALYSIS 2026

Johnson & Johnson (NYSE: JNJ) is trading near its all-time high of $276.47, up more than 50% over the past 12 months — one of the stronger runs among major healthcare stocks this year.

What's behind it:

The company posted a strong second quarter, with revenue of $25.3 billion (+5.6% operationally) and adjusted earnings per share of $2.90, beating estimates. Management raised full-year guidance and now expects to cross $100 billion in annual revenue for the first time. Growth is being led by the Innovative Medicine segment, with cancer and immunology drugs like DARZALEX, TREMFYA and CARVYKTI all performing well, alongside newer launches such as ICOTYDE.

Where the risks are:

The company's older immunology drug STELARA continues to lose sales to biosimilar competitors, acting as a persistent drag on growth. In its MedTech division, a China inventory issue and softer data on the Abiomed heart pump have slowed momentum, though management describes this as temporary.

The biggest overhang remains legal: J&J has proposed a $5.5 billion settlement covering roughly 76,000 talc-related ovarian cancer lawsuits, but the deal requires approval from 95% of eligible claimants to move forward — and a separate $10 million jury verdict in Louisiana this month is a reminder that not all cases are covered.

On valuation, the stock now trades at about 31 times trailing earnings, a premium to peers like Pfizer, Merck and AbbVie. Wall Street analysts remain broadly positive, with an average price target close to where the stock is already trading — suggesting much of the recent good news may already be priced in.

Johnson & Johnson also remains a "Dividend King," having raised its dividend for more than 60 consecutive years, though the current yield of under 2% is on the lower end of its own historical range given how far the share price has climbed.

Full breakdown of the business, competitors, latest earnings and dividend history in the article — link below. This is not investment advice.

👉 Read the full analysis: https://steady.page/en/dividends/posts/446df21a-4de7-42d5-9a91-5e6986c1f647

by the way...if you like this list and you want more tables like the above published, please help us now. Please read the following text to understand why we need your help. Thank you.

I've been working on this blog for years, without much success. But many people got a lot of inspirational information from my work - for free. I think that's good, but unfortunately I have my own expenses, a wife and children. That's why I need your support to keep the blog up and running.

You can easily support our project on the crowdfunding platform Steady. It's an alternative to Patreon. 

As a small gift for your support, you will receive monthly updated lists of the best dividend growth stocks in the world -- stock lists from USA, Canada and Japan with over 1.100 long-term dividend growth stocks.

You can use these lists to display, modify, calculate and sort important key figures such as the dividend yield, return on equity ratio, FCF-Yield or price-to-book-ratio. Over 40 ratios are available for sorting. The lists are updated once a month and will be free to use for all supporter on Steady.

If you want to know how the Excel-Spreadsheet looks like, you can view a sample file on Google Spreadsheets. Just follow the link and you get an idea how it works for you. 

As I said, this is just a sample file. With your help, these Excel-Spreadsheets can be developed further. All I need is a support from you. Please participate in one of the programs listed below and support our project.

INSERT_STEADY_CHECKOUT_HERE

With your support, the project can remain financially independent and can be further developed without annoying advertising or paywalls.

Thank you so much for your support! If you don't have the financial flexibility to help me, you can easily share this project or post with your social connections on Facebook, Twitter, Instagam, Pinterest or TikToc. It could be a great way to keep this site alive. Thank you so much.

Why Steady?

Steady is a crowdfunding platform for creatives, photographers, journalists and content creators. All of these groups have the same problem: they do an honest job but have no way to monetize it. At the same time, they do not advertise or get support from partners in order to maintain their independence.

Steady gives us the opportunity to receive regular support for project implementation. In this way, the internet can continue to exist as a free medium of opinion.

If you are unable to support us financially, we are not worry. You can also help us by telling your friends about us on Facebook, Twitter, Instagram, Tik Tok or another social channel. The more support we have, the more we can invest in the content and expand the database. Thank you so much!